SCHEMBL19950262

SCHEMBL19950262

CN1CCN(c2ncc(-c3nn(C(=O)O)c4cnc(Cl)cc34)cn2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FURIN P09958 4/20 0.39
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
TNKS O95271 2/20 0.38
MELK Q14680 2/20 0.37
HTR3A P46098 1/20 0.36
USP2 O75604 4/20 0.35
ALDH1A1 P00352 4/20 0.35
CASP1 P29466 4/20 0.35
CASP7 P55210 4/20 0.35
KDM4E B2RXH2 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PRKAB2 O43741 1/20 0.35
PRKAG1 P54619 1/20 0.35
PRKAA2 P54646 1/20 0.35
PRKAA1 Q13131 1/20 0.35
PRKAG3 Q9UGI9 1/20 0.35
PRKAG2 Q9UGJ0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19950539 0.86 TNKS (0.43) HDAC3HDAC2HDAC8TNKSMELK
SCHEMBL19950082 0.86 CHEK1 (0.45) HDAC3HDAC2MELKALDH1A1PRKAB2
SCHEMBL19950137 0.86 GPR119 (0.39) FURINHDAC3HDAC1HDAC2HDAC8
SCHEMBL29746518 0.86 GPR119 (0.39) FURINHDAC3HDAC1HDAC2HDAC8
SCHEMBL19948887 0.80 SMN1; SMN2 (0.38) FURINHDAC3HDAC1HDAC2HDAC8
SCHEMBL19950410 0.78 CREBBP (0.41) MAPK1
SCHEMBL29746799 0.74 RET (0.44) TNKS
SCHEMBL19950284 0.74 RET (0.44) TNKS
SCHEMBL19950549 0.73 MAPT (0.39) HDAC3HDAC2MELKALDH1A1PRKAB2
SCHEMBL29746742 0.73 MAPT (0.39) HDAC3HDAC2MELKALDH1A1PRKAB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795166-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2023-10-24 US disclosed
EP-4119558-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF Incyte Corporation (US) 2023-01-18 EP disclosed
EP-3510032-B1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORP (US) 2022-07-06 EP disclosed
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2021-12-09 US disclosed
US-10934288-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2021-03-02 US disclosed
US-20200087301-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2020-03-19 US disclosed
US-10435405-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-10-08 US disclosed
EP-3510032-A1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER Incyte Corporation (US) 2019-07-17 EP disclosed
US-10266530-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2019-04-23 US disclosed
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-04-11 US disclosed
WO-2018049200-A1 PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-03-15 WO disclosed
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200087301-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 FURIN 3937/4885HDAC3 1696/4885HDAC1 951/4885
US-11795166-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 FURIN 3937/4885HDAC3 1696/4885HDAC1 951/4885
US-20180072720-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 FURIN 3937/4885HDAC3 1696/4885HDAC1 951/4885
US-10934288-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 FURIN 3937/4885HDAC3 1696/4885HDAC1 951/4885
US-20210380581-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 FURIN 3937/4885HDAC3 1696/4885HDAC1 951/4885
US-10435405-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 FURIN 3937/4885HDAC3 1696/4885HDAC1 951/4885
US-20190106419-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 FURIN 3937/4885HDAC3 1696/4885HDAC1 951/4885
US-10266530-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 FURIN 3937/4885HDAC3 1696/4885HDAC1 951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.